Were Analysts Bullish Cardiome Pharma Corp. (NASDAQ:CRME) This Week?

February 15, 2018 - By Louis Casey

 Were Analysts Bullish Cardiome Pharma Corp. (NASDAQ:CRME) This Week?
Investors sentiment increased to 1.09 in Q3 2017. Its up 0.26, from 0.83 in 2017Q2. It improved, as 2 investors sold Cardiome Pharma Corp. shares while 9 reduced holdings. 7 funds opened positions while 5 raised stakes. 13.54 million shares or 10.92% less from 15.20 million shares in 2017Q2 were reported.
Royal Bank Of Canada has invested 0% in Cardiome Pharma Corp. (NASDAQ:CRME). Putnam Invs Limited Liability Corporation reported 3.09M shares. Group One Trading Lp reported 0% stake. Knott David M reported 0.12% stake. Westfield Capital Mgmt Lp holds 0.08% or 4.86 million shares in its portfolio. Moreover, Bancorp Of Nova Scotia Com has 0% invested in Cardiome Pharma Corp. (NASDAQ:CRME) for 10 shares. Moreover, Geode Management Limited Company has 0% invested in Cardiome Pharma Corp. (NASDAQ:CRME). Art Advsr Llc has invested 0% in Cardiome Pharma Corp. (NASDAQ:CRME). Ardsley Advisory Prns has invested 0.01% of its portfolio in Cardiome Pharma Corp. (NASDAQ:CRME). Wells Fargo & Com Mn owns 800 shares. Rock Springs Management L P accumulated 1.20 million shares. Moreover, Scotia Capital Inc has 0% invested in Cardiome Pharma Corp. (NASDAQ:CRME). Jefferies Grp Llc has 10,000 shares for 0% of their portfolio. 45 were accumulated by Financial Bank Of America Corporation De. 51,400 were accumulated by Pnc Fincl Service Group.

Cardiome Pharma Corp. (NASDAQ:CRME) Ratings Coverage

Among 6 analysts covering Cardiome Pharma Corp (NASDAQ:CRME), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cardiome Pharma Corp had 15 analyst reports since August 11, 2015 according to SRatingsIntel. The company was maintained on Wednesday, November 22 by H.C. Wainwright. H.C. Wainwright maintained the shares of CRME in report on Tuesday, August 22 with “Buy” rating. The stock of Cardiome Pharma Corp. (NASDAQ:CRME) earned “Buy” rating by LB Securities on Friday, August 14. The rating was maintained by Brean Capital with “Buy” on Friday, March 11. The company was maintained on Wednesday, November 15 by Canaccord Genuity. The firm has “Outperform” rating by Leerink Swann given on Thursday, December 22. Zacks downgraded Cardiome Pharma Corp. (NASDAQ:CRME) on Wednesday, August 26 to “Hold” rating. On Tuesday, August 11 the stock rating was downgraded by Zacks to “Buy”. Mackie downgraded Cardiome Pharma Corp. (NASDAQ:CRME) on Wednesday, October 12 to “Hold” rating. The rating was reinitiated by Canaccord Genuity with “Buy” on Monday, July 17. Below is a list of Cardiome Pharma Corp. (NASDAQ:CRME) latest ratings and price target changes.

15/12/2017 Broker: Mackie Rating: Buy Upgrade
22/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $9.5 Maintain
15/11/2017 Broker: Canaccord Genuity Rating: Buy Old Target: $8 New Target: $5 Maintain
22/08/2017 Broker: H.C. Wainwright Rating: Buy New Target: $9.5 Maintain
21/08/2017 Broker: Canaccord Genuity Rating: Buy New Target: $8.0 Maintain

The stock increased 0.48% or $0.007 during the last trading session, reaching $1.467. About 13,876 shares traded. Cardiome Pharma Corp. (NASDAQ:CRME) has declined 11.02% since February 15, 2017 and is downtrending. It has underperformed by 27.72% the S&P500.

Cardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of patients suffering from heart diseases. The company has market cap of $49.35 million. It offers BRINAVESS ) for the conversion of recent onset atrial fibrillation to sinus rhythm in adults; and AGGRASTAT, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. It currently has negative earnings. The firm also provides ESMOCARD and ESMOCARD LYO short-acting beta-blockers used to control rapid heart rate; XYDALBA, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections; and TREVYENT for the treatment of pulmonary arterial hypertension.

More news for Cardiome Pharma Corp. (NASDAQ:CRME) were recently published by: Seekingalpha.com, which released: “Cardiome Pharma: The Pieces Are Coming Together” on May 25, 2017. Prnewswire.com‘s article titled: “Cardiome to Present at the Leerink Partners 7th Annual Global Healthcare …” and published on February 08, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.